touchTALKS What’s on the horizon for higher-risk MDS? An update on emerging novel agents
Dr David Sallman reviews advances in HR-MDS management, including the mode of action and latest clinical data for emerging treatments.
Novel treatments for HR-MDS: What’s on the horizon?
Dr David Sallman describes updates to the classification of HR-MDS and outlines the mode of action of emerging treatments.
view bio and disclosures 1/3 Next ChapterEfficacy data for emerging treatments for patients with HR-MDS
Dr David Sallman discusses the latest clinical trials and efficacy data for emerging treatments for HR-MDS.
view bio and disclosures 2/3 Next ChapterSafety data for emerging treatments for patients with HR-MDS
Dr David Sallman summarizes the safety findings and strategies for managing adverse events observed with emerging treatments for HR-MDS.
view bio and disclosures 3/3 Take CE/CME TestOverview & Learning Objectives
Overview
Dr David Sallman, a leading expert in the treatment of higher-risk myelodysplastic neoplasms (HR-MDS), discusses the impact that emerging treatment options may have on clinical practice. He covers the latest updates to the classification of HR-MDS; outlines the mode of action of emerging agents; and discusses clinical evidence on their efficacy and safety, including the most recent data presented at the American Society of Hematology (ASH) Annual Meeting and Exposition 2022.
This activity is jointly provided by USF Health and touchIME. read more
Target Audience
This activity has been designed to meet the educational needs of oncologists and haematologists involved in the management of HR-MDS.
Disclosures
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Faculty
Dr David Sallman discloses: Advisory board or panel fees from AvenCell, bluebird bio, Bristol Myers Squibb, Intellia Therapeutics, Jasper Therapeutics, Kite Pharma, Novartis, Servier, Shattuck Labs and Syndax. Consultancy fees from AbbVie, Affimed, Gilead, Molecular Partners AG, Precigen Therapeutics Inc, Takeda and Zentalis Pharmaceuticals. Grants or research support from Aprea and Jazz Pharmaceuticals. Speaker’s bureau fees from Bristol Myers Squibb, Incyte and Servier.
Content reviewer
Alicia Canalejo, APRN has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Adriano Boasso has no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact cpdsupport@usf.edu
Accreditations
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu)
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 14 February 2023. Date credits expire: 14 February 2024.
If you have any questions regarding credit please contact cpdsupport@usf.edu
Learning Objectives
After watching this activity, participants should be better able to:
- Recall the mechanisms of action for key emerging treatments for patients with HR-MDS
- Describe the latest efficacy data for key emerging treatments for patients with HR-MDS
- Discuss the safety profile of key emerging treatments for patients with HR-MDS
Faculty & Disclosures
Dr David Sallman
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA
David Sallman, MD, is an assistant member in the Department of Malignant Hematology at Moffitt Cancer Center, and assistant professor in the Department of Oncologic Sciences at the University of South Florida in Tampa, FL, USA. read more
Dr Sallman’s interests are myelodysplastic neoplasms (MDS) and acute myeloid leukaemia (AML). His research focuses on the development of targeted therapeutic strategies for patients with MDS and AML, based on the underlying mutational drivers of each disease. Specifically, he studies the genetic drivers of myeloid diseases to improve prognostication for patients and to allow for more personalized treatment.
He has been the lead principal investigator for phase I, II and III trials in patients with TP53 mutant MDS and AML. Dr Sallman also serves as lead principal investigator for multiple cellular therapy trials including chimeric antigen receptor cell therapy (CAR-T) and T-cell receptor therapy (TCR).
Dr Sallman has authored and co-authored numerous articles, books, book chapters and abstracts, and serves as a reviewer for multiple journals. He received a Young Investigator grant from the MDS Foundation in 2017 and was awarded a Career Development grant from the Vera and Joseph Dresner Foundation in 2018.
Dr David Sallman discloses: Advisory board or panel fees from AvenCell, bluebird bio, Bristol Myers Squibb, Intellia Therapeutics, Jasper Therapeutics, Kite Pharma, Novartis, Servier, Shattuck Labs and Syndax. Consultancy fees from AbbVie, Affimed, Gilead, Molecular Partners AG, Precigen Therapeutics Inc, Takeda and Zentalis Pharmaceuticals. Grants or research support from Aprea and Jazz Pharmaceuticals. Speaker’s bureau fees from Bristol Myers Squibb, Incyte and Servier.
REGISTER NOW FOR FREE ACCESS TO
- 1000+ topical and insightful peer-reviewed journal articles
- 100+ hours of bite-sized congress highlights
- 8 major therapy areas packed with the latest scientific advances
- 150+ specialties offering learn-on-the-go medical education
- + Concise email updates and newsletters so you never miss out
